RNAC Stock - Cartesian Therapeutics, Inc.
Unlock GoAI Insights for RNAC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $38.91M | $26.00M | $110.78M | $85.08M | $16.60M |
| Gross Profit | $38.91M | $26.00M | $108.74M | $85.08M | $16.60M |
| Gross Margin | 100.0% | 100.0% | 98.2% | 100.0% | 100.0% |
| Operating Income | $-43,897,000 | $-86,416,000 | $14.54M | $-4,597,000 | $-56,821,000 |
| Net Income | $-77,424,000 | $-219,710,000 | $35.38M | $-25,687,000 | $-68,876,000 |
| Net Margin | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% |
| EPS | $-2.99 | $-49.76 | $7.33 | $-6.74 | $-20.42 |
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 9th 2025 | Wedbush | Initiation | Outperform | $38 |
| December 19th 2024 | BTIG Research | Initiation | Buy | $42 |
| August 6th 2024 | TD Cowen | Initiation | Buy | - |
| July 2nd 2024 | Oppenheimer | Downgrade | Perform | - |
| June 4th 2024 | Oppenheimer | Initiation | Outperform | $50 |
| May 24th 2024 | Mizuho | Initiation | Buy | $40 |
| April 23rd 2024 | H.C. Wainwright | Reiterated | Buy | $54← $2 |
| April 23rd 2024 | Leerink Partners | Initiation | Outperform | $39 |
Earnings History & Surprises
RNACEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.82 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.81 | $-1.38 | -70.4% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.76 | $0.50 | +165.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.61 | $-0.68 | -11.5% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.78 | $-0.59 | +24.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.78 | $-0.69 | +11.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.07 | $0.54 | +150.5% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.81 | $-1.97 | -143.2% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.30 | $-2.40 | -700.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-2.10 | $-2.40 | -14.3% | ✗ MISS |
Q3 2023 | Aug 17, 2023 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-2.60 | $-0.17 | +93.5% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-2.17 | $0.05 | +102.1% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-0.17 | $-0.06 | +63.9% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | $-2.27 | $0.07 | +103.1% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | — | $0.27 | — | — |
Q4 2021 | Dec 30, 2021 | $-3.35 | $0.12 | +103.5% | ✓ BEAT |
Q3 2021 | Sep 29, 2021 | — | $-0.19 | — | — |
Q2 2021 | Jun 29, 2021 | — | $0.05 | — | — |
Latest News
Cartesian rebounds after insider purchase
📈 PositiveHC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $30
📈 PositiveBTIG Maintains Buy on Cartesian Therapeutics, Raises Price Target to $44
📈 PositiveCartesian Therapeutics Data From Phase 2 Study Of Descartes-08 Demonstrates 100% Lupus Low Disease Activity State Response Rate In Participants With Systemic Lupus Erythematosus
📈 PositiveCartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estimate
➖ NeutralCartesian climbs as Wedbush starts with Overweight on cell therapy platform
📈 PositiveFrequently Asked Questions about RNAC
What is RNAC's current stock price?
What is the analyst price target for RNAC?
What sector is Cartesian Therapeutics, Inc. in?
What is RNAC's market cap?
Does RNAC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RNAC for comparison